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The International Diabetes Foundation estimates that 382 million people worldwide have diabetes, and projects that this number will rise to 592 million people by the year 2035 (IDF Diabetes Atlas, 2013). 
In the United States alone, nearly 26 million people (8.3% 
of the population) are affected by diabetes, with 1.9 million 
new cases diagnosed each year. Prevalence of diabetic neu-
ropathy varies by population and socioeconomic status, but 
a recent large-scale, community-based study from England 
found that almost 50% of diabetic patients showed signs of 
clinical neuropathy (defined as the inability to detect pin-
prick sensation, vibration, differences in temperature, and 
Achilles reflex). Twenty-one percent of these patients com-
plained of painful neuropathic symptoms, compared with 
26% of patients without clinical neuropathy who complained 
of painful neuropathic symptoms (Abbott, Malik, van Ross, 
Kulkarni, & Boulton, 2011).
Neuropathic syndromes are classified as acute, if they last 
less than three months, or chronic, if they last longer than 
three months (Bouhassira, Lantéri-Minet, Attal, Laurent, 
& Touboul, 2008). Chronic diabetic neuropathic pain syn-
dromes tend to be more debilitating than their acute coun-
terparts, and present with symptoms ranging from mild 
dysesthesias to severe, unremitting pain. The pain itself 
may be completely stimulus-independent or evoked only 
with mechanical, thermal, or chemical stimulation (Jose, 
Bhansali, Hota, & Pandhi, 2007; Morello, Leckband, Stoner, 
Moorhouse, & Sahagian, 1999; Vinik, Park, Stansberry, & 
Pittenger, 2000).
The exact pathophysiology of chronic neuropathic pain in 
diabetes has not yet been identified and is believed to be 
multifactorial in nature. Several mechanisms have been pos-
ited over the years, and both the peripheral and central ner-
vous system have been implicated. Hyperglycemia clearly 
plays a role, and even slight perturbations in blood-glucose 
levels, as seen in impaired glucose tolerance, can precipitate 
nerve damage and dysfunction (Smith & Singleton, 2008). 
Hyperglycemia increases nonenzymatic glycation of struc-
tural proteins and polyol accumulation, alters protein kinase 
C activity, decreases nitric oxide, and increases poly ADP-
ribose polymerase activation, causing oxidative stress and 
resultant nerve damage and impaired nerve repair (Tavakoli, 
Mojaddidi, Fadavi, & Malik, 2008; Tomlinson, 1999). There 
are also microangiopathic changes that parallel and often 
precede apparent nerve-fiber injury (Dyck & Giannini, 1996; 
Malik et al., 2005; Thrainsdottir et al., 2003).
Studies conducted on sural nerve biopsies obtained from 
diabetic patients with clinically confirmed neuropathies 
demonstrate progressive length-dependent nerve fiber loss 
(Yagihashi, 1995). Ongoing nerve damage and impaired 
repair lead to peripheral hyperexcitability with lowered 
activation thresholds and spontaneous neuronal discharge 
(Krishnan & Kiernan, 2005). This activity is perceived by 
patients as spontaneous pain and dysesthesia, or as an 
exaggerated response to noxious or otherwise benign stim-
uli. With increasing neuronal loss, positive symptoms even-
tually give way to negative symptoms such as sensory loss. 
In a subset of patients, however, positive symptoms fail to 
resolve, which hints at a role for centrally mediated or psy-
chiatric mechanisms in the abnormal sensations.
There is increasing evidence that psychosocial factors 
may be involved in the pathophysiology of chronic dia-
betic neuropathic pain (Calcutt, 2002). Individuals with 
diabetic polyneuropathy exhibit significantly higher rates 
of axis I psychiatric disorders—especially anxiety disorders 
and major depressive disorders—compared with diabetic 
patients without neuropathy. Moreover, the severity of the 
depressive symptoms correlates positively and significantly 
with the severity of the neuropathic symptoms (Moreira 
et al., 2007). However, the chronological order and inter-
play between neuropathic pain and psychiatric illness still 
remain unclear. There is ample evidence that chronic painful 
neuropathy can lead to physical impairments and impose 
functional limitations that drastically lower the level of 
patients’ effective well-being (Benbow, Wallymahmed, & 
MacFarlane, 1998; Rijken et al., 1998). Patients complain of 
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There is increasing evidence that psychosocial factors may 
be involved in the pathophysiology of chronic diabetic 
neuropathic pain. Individuals with diabetic polyneuropathy 
exhibit significantly higher rates of axis I psychiatric disor-
ders, and worsening neuropathic symptoms correlate with 
worsened psychiatric illness. This association exists even 
when social-support and quality-of-life measures are con-
trolled. Aberrant supraspinal structures and neuronal net-
works in diabetic neuropathy mimic those found in other 
psychiatric illnesses. Response to standard medications 
and therapeutic approaches remains unsatisfactory, and 
antidepressants continue to serve as first-line treatment 
for diabetic neuropathy. The exact interplay between neu-
ropathic pain and psychiatric illness remains unclear and 
may have a common pathophysiological focus. This area 
of study needs to be revisited and psychological interven-
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disturbances in mood, sleep, work, and activities of daily liv-
ing, all of which can lead to increases in depression, anxiety, 
and anger (Robinson, Yateman, Protopapa, & Bush, 1990; 
Watkins, 1984; Zelman, Brandenburg, & Gore, 2006). When 
beset by unremitting pain, patients may lose their coping 
mechanisms and become overly sensitive to and preoccu-
pied with their neuropathic symptoms (Feldman, Downey, 
& Schaffer-Neitz, 1999). Neuropathy has been found to be 
significantly associated with depression, even when the 
analyses control for social-support and quality-of-life mea-
surements (Yoshida, Hirai, Suzuki, Awata, & Oka, 2009). 
Stress, anxiety, and depression are also highly associated 
with the development of diabetes. Large prospective epi-
demiological studies and meta-analyses suggest a bidirec-
tionality and, therefore, a common pathogenesis underlying 
diabetes and psychiatric disorders (Engum, 2007; Knol et 
al., 2006; Mezuk, Eaton, Albrecht, & Golden, 2008; Pan et 
al., 2010; Pouwer, Kupper, & Adriaanse, 2010).
A basis for mood disorders and preoccupation with neuro-
pathic symptoms in diabetic patients may be found in stud-
ies of neuronal networks and connectivity. Cauda et al. (2009) 
studied a group of eight diabetics suffering from painful 
neuropathy and compared them with healthy controls using 
functional magnetic resonance imaging. They found that 
neuropathic patients had reduced default mode network 
(DMN) connectivity while showing increased connectivity 
among several frontal areas, insulae, and thalami (Cauda et 
al., 2009). The DMN refers to a network of brain regions 
composed of the medial prefrontal cortex, the posterior 
cingulate cortex/precuneus, and the lateral posterior corti-
ces. This network is known to be most active during states 
of wakeful rest, and least active during task-related cogni-
tive processes (Fox et al., 2005). The DMN has been found 
to be significantly affected in Alzheimer’s disease, autism, 
schizophrenia, post-traumatic stress disorder, and depres-
sion (Andreescu et al., 2013; Buckner, Andrews-Hanna, & 
Schacter, 2008; Cisler, Scott Steele, Smitherman, Lenow, 
& Kilts, 2013). Since the DMN underlies self-reflection and 
modulation of emotion, reduced activity in patients with 
chronic neuropathy suggests that they have a decreased 
ability to regulate pain and emotions while spending more 
cognitive resources in the catastrophization of pain. 
Several supraspinal structural abnormalities have also been 
implicated in painful diabetic neuropathy and involve the 
thalamus in particular. Selvarajah et al. (2008) found that 
patients with diabetic peripheral neuropathy had signifi-
cantly lower ratios of thalamic N-acetyl aspartate (NAA) to 
creatine and of NAA to choline compared with controls. 
Sorensen, Siddall, Trenell, and Yue (2008) also studied NAA 
levels in the thalami of diabetic patients and found that 
patients with chronic pain had markedly reduced levels of 
the compound compared with diabetic patients without 
pain. NAA is a free amino acid in the brain and is commonly 
used as an internal standard for neuronal integrity and activ-
ity. It is often used in the study of psychiatric conditions and 
has been found to be significantly reduced in the thalami 
of patients suffering from depression (Huang et al., 2010), 
schizophrenia (Kraguljac et al., 2012; Tandon et al., 2013), 
cognitive impairment (Salem et al., 2008), restless legs 
syndrome, essential tremors (Kendi, Tan, Kendi, Erdal, & 
Tellioglu, 2005), and substance abuse (Li, Wang, Pankiewicz, 
& Stein, 1999). The underlying mechanism of thalamic dys-
function in these conditions is currently unclear, especially in 
light of the thalamus’s innumerable functions. However, the 
thalamus’s role in movement, pain perception and modu-
lation, and identification of emotional information, and its 
generation of affective states, are increasingly being recog-
nized. It is not unlikely, therefore, that thalamic dysfunction 
underlies the psychiatric component of the pathophysiol-
ogy of diabetic chronic neuropathic pain, as either a primary 
or a secondary process. 
Neuropathic pain responds poorly to standard therapeutic 
approaches, and a large percentage of patients remains 
refractory to the therapies available despite an ever-increas-
ing catalogue of drugs (Vinik et al., 2000). More than half of 
the patients do not respond to treatment, and those who 
do respond report only a 30% to 40% reduction in pain 
(Dworkin et al., 2010; O’Connor, 2009; Turk, 2002). There 
is little agreement about the optimal treatment regimen for 
neuropathic pain, though many different guidelines exist 
(Attal et al., 2010; Bril et al., 2011; Dworkin et al., 2007; 
Moulin et al., 2007). There is some agreement about which 
classes of medicine seem to work better, with first-line treat-
ments including antidepressants (tricyclic antidepressants, 
selective norepinephrine reuptake inhibitors), calcium chan-
nel alpha 2-delta ligands (pregabalin), and topical lidocaine. 
The effectiveness of antidepressants in the treatment of 
neuropathic pain lends further support to the notion that 
a psychiatric etiology plays at least some role in the condi-
tion’s modulation. Second-line medications consist of opioid 
analgesics and tramadol, while third-line treatments include 
such medications as capsaicin, mexiletine, and N-methyl-d-
aspartate receptor antagonists (O’Connor & Dworkin, 2009).
Psychological interventions for neuropathic pain have 
received little attention, but they are supported by con-
siderable data and empirical evidence of benefit in the 
management of heterogeneous chronic pain conditions 
(Brunelli & Gorson, 2004; Flor, Fydrich, & Turk, 1992). These 
psychological interventions focus on the emotional distress 
and maladaptive behaviors that accompany and exacerbate 
pain, and teach patients to adapt and manage their lives in 
the face of unrelenting, chronic pain (Turk, Audette, Levy, 
Mackey, & Stanos, 2010). Some interventions suggested 
for treatment of neuropathic pain include biofeedback, 
hypnosis, social support, operant behavioral interventions, 
and cognitive behavioral interventions (Haythornthwaite 
& Benrud-Larson, 2000, 2001; Turk et al., 2010). Operant 
conditioning refers to a treatment approach wherein rein-
forcement is used to promote positive behaviors while dis-
couraging maladaptive behaviors. In the context of diabetic 
neuropathy, this approach discourages healthcare profes-
sionals from positively reinforcing ostensible pain-associ-
ated behaviors such as limping and griping about the pain. 
Cognitive behavioral interventions differ from operant con-
ditioning in that they additionally target internal cognitive 
reasoning in patients, helping them develop coping mecha-
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nisms and, as a result, a sense of control over their pain. 
Biofeedback employs quantifiable, physiological metrics 
(such as blood pressure, heart rate, and sweat-gland activity) 
and makes them available to patients in real time to bring 
unconscious thoughts and behaviors that exacerbate pain 
under conscious control (Turk et al., 2010).
Although the role of psychological modalities in the treat-
ment of chronic neuropathic pain has historically been lim-
ited, there is increasing evidence that pain reduction using 
these methods rivals that observed with more-traditional 
pharmacological treatments (Otis et al., 2013; Turk et al., 
2010). As individual treatments have met with very limited 
success, psychological modalities provide a promising com-
plement to medical therapy in achieving better outcomes 
for patients. 
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